BYD
6.12.2023 13:07:31 CET | Business Wire | Press release
BYD Ecuador (hereafter referred to as BYD) and the Latin American Energy Organization (OLADE) announced that an Interinstitutional Cooperation Agreement was formalized recently, with the aim of advancing the cause of electric mobility in Latin America and the Caribbean.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206085642/en/
BYD and OLADE Form Strategic Partnership (Left: Executive Secretary of OLADE, Andrés Rebolledo Smitmans; Right: Country Manager of BYD Ecuador, Jorge Burbano) (Photo: Business Wire)
OLADE, under the leadership of its Executive Secretary, Andrés Rebolledo Smitmans, and BYD, represented by Jorge Burbano, Country Manager of BYD Ecuador, have signed this agreement, solidifying their joint commitment to promoting electric vehicles and accelerating energy transitions in the region.
Established in 1973, OLADE is a respected intergovernmental cooperation organization dedicated to fostering energy integration, development, and conservation in Latin America and the Caribbean. In contrast, BYD, founded in 1995, stands as a leading technology company with a focus on innovation in diverse industries, including automobiles, electronics, rail transit, and new energy.
The collaboration outlined in this agreement will encompass crucial elements such as promoting sustainable mobility, conducting workshops, and providing specialized training in electromobility. These initiatives will target both the public and private sectors, academia, specialized guilds, and civil society in Latin America and the Caribbean. Moreover, the partnership will involve site visits and technical demonstrations at OLADE facilities, specifically focusing on electromobility, for universities, technology centers, educational institutions, guilds, and related organizations. Additionally, BYD’s vehicles will be utilized in OLADE’s electromobility studies, aligning with OLADE’s work plans.
BYD will significantly contribute to this collaboration by providing a TANG EV electric vehicle model along with a charging station. This equipment will be used to demonstrate the electric infrastructure and the vehicle's autonomy, emphasizing the advantages of electric vehicles.
Commenting on the partnership, Jorge Burbano, Country Manager of BYD Ecuador, stated, “We are deeply honored to collaborate with OLADE, leveraging our expertise in electric mobility and energy solutions. Our joint mission is crucial – reducing CO2 emissions and contributing to global efforts to cool the earth by 1℃. I am confident that our cooperation will serve as a beacon for knowledge transfer and research, fostering sustainable development and energy security in the region.”
The Executive Secretary of OLADE, Andrés Rebolledo, highlighted the significance of the recent agreement as a key commitment to regional energy integration and cooperation for the benefit of OLADE’s 27 member countries. He emphasized the importance of transitioning to a sustainable vision in Latin America and the Caribbean, advocating for a long-term perspective in energy integration. This milestone signifies a notable collaboration between both entities, dedicated to a cleaner and more sustainable future for the region. It focuses on priority areas such as electrification of mobility and sustainable mobility training, with the possibility of agreeing on specific agreements for the execution of projects aligned with their shared objectives.
Through this agreement, BYD and OLADE reaffirm their dedication to regional energy integration and cooperation for the benefit of member countries. By closely collaborating and implementing joint projects, they aim to promote sustainable development and optimize energy resources and transportation through clean energy sources in the region.
About BYD
BYD is a multinational high-tech company devoted to leveraging technological innovations for a better life. Founded in 1995 as a rechargeable battery maker, BYD now boasts a diverse business scope covering automobiles, rail transit, new energy, and electronics, with over 30 industrial parks in China, the United States, Canada, Japan, Brazil, Hungary, and India. From energy generation and storage to its applications, BYD is dedicated to providing zero-emission energy solutions that reduce global reliance on fossil fuels. Its new energy vehicle footprint now covers 6 continents, over 70 countries and regions, and more than 400 cities. Listed in both Hong Kong and Shenzhen Stock Exchanges, the company is known to be a Fortune Global 500 enterprise that furnishes innovations in pursuit of a greener world.
For more information, please visit www.bydglobal.com.
About BYD Auto
Founded in 2003, BYD Auto is the automotive subsidiary of BYD, a multinational high-tech company devoted to leveraging technological innovations for a better life. Aiming to accelerate the green transition of the global transportation sector, BYD Auto focuses on developing pure electric and plug-in hybrid vehicles. The company has mastered the core technologies of the entire industrial chain of new energy vehicles, such as batteries, electric motors, electronic controllers, and automotive-grade semiconductors. It has witnessed in recent years significant technological advancements, including the Blade Battery, DM-i Super Hybrid Technology, e Platform 3.0, CTB Technology, e4 Platform, BYD DiSus Intelligent Body Control System, and DMO super hybrid system. The company is the world’s first carmaker to stop the production of fossil-fueled vehicles on EV shift and has remained top of new energy passenger vehicle sales in China for 10 years in a row.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231206085642/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom